Cytomegalovirus T Cell Immunity and Antiviral Prophylaxis Minimization in Lung Transplant Recipients
Status: Recruiting
Location: See location...
Intervention Type: Drug, Diagnostic test, Device
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
• Pre-existing serological immunity to CMV (R+)
• Able and willing to provide informed consent
Locations
United States
New York
NYU Langone Health
RECRUITING
New York
Contact Information
Primary
Tyler Lewis
Tyler.lewis@nyulangone.org
866-838-5864
Time Frame
Start Date: 2024-09-13
Estimated Completion Date: 2026-09
Participants
Target number of participants: 50
Treatments
Experimental: Lung Transplant Recipients
Lung transplant recipients with pre-transplant serological immunity to CMV. CMV-TCIP will be measured every 3 months post-transplant with antiviral prophylaxis discontinued when threshold is exceeded.
Related Therapeutic Areas
Sponsors
Collaborators: Viracor Eurofins
Leads: NYU Langone Health